BriaCell Therapeutics (TSE:BCT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BriaCell Therapeutics has received approval from the Data Safety Monitoring Board to continue its Phase 3 study of a novel immunotherapy for metastatic breast cancer, a promising development under FDA Fast Track Designation. The study’s continuation without protocol modifications marks a significant step forward for the company’s innovative cancer treatment.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
